FDA warnings cut antipsychotic use 19 pct: study

CHICAGO Mon Jan 11, 2010 5:39pm EST

A woman in a wheelchair leaves a therapy session for residents affected by dementia at a home for the elderly in Hamburg July 14, 2009. REUTERS/Christian Charisius

A woman in a wheelchair leaves a therapy session for residents affected by dementia at a home for the elderly in Hamburg July 14, 2009.

Credit: Reuters/Christian Charisius

Related Topics

CHICAGO (Reuters) - Strong warnings about the dangers of giving antipsychotic drugs to patients with dementia have reduced use of the drugs in these patients by a "modest" 19 percent, U.S. researchers said on Monday.

Studies have shown that using antipsychotic drugs shortens the lives of elderly patients with dementia. The U.S. Food and Drug Administration issued a warning about the drugs in 2005.

"We concluded that it resulted in a modest reduction," said Dr. Ray Dorsey of the University of Rochester Medical Center in New York, who conducted a six-year study along with colleagues, said of the warning.

Dorsey said the group does not have enough data to say how many people benefited from the warning, and he did not cast the results as a sign of its success or failure.

"It's hard to say whether 20 percent is the right number," Dorsey said. He said previous health warnings have had mixed results.

The team analyzed nationally representative data on the use of atypical antipsychotic drugs between January 2003 and December 2008.

Dr. Paula Rochon of the Women's College Research Institute in Toronto suggested the warning did little to decrease use.

"Regulatory agency messages about the risks and benefits of antipsychotic therapy in the care of older people with dementia appear to have little effect on prescribing," she wrote in a commentary.

Antipsychotic drugs have been used widely to control behavioral problems in elderly dementia patients such as those with Alzheimer's disease.

Common antipsychotic drugs include Johnson & Johnson's Risperdal, known generically as risperidone; Eli Lilly and Co's Zyprexa or olanzapine; Bristol-Myers Squibb's Abilify or aripiprazole; and AstraZeneca's Seroquel or quetiapine.

Rochon and colleague Dr. Geoffrey Anderson said the warnings for antipsychotic drugs were not specific and should more clearly state the dangers of giving the drugs to older patients.

In the United States, once a drug is approved, doctors are free to use it in patients as they see fit, but companies are only allowed to market the drug for the approved use.

(Editing by Maggie Fox and Steve Gutterman)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
DanielHaszard wrote:
Eli Lilly has made $40 billion on $10 a pill Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.

Zyprexa was pushed by Lilly Drug Reps.
They called it the “Five at Five” (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and “VIVA ZYPREXA” (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.

I am a living example of Zyprexa gone/done wrong was given it 1996-2000 off-label for PTSD got sudden high blood sugar A1C 14.7 in January 2000.The stuff was worthless for my condition PTSD and cost me thousands in co-pays gave me diabetes.

Daniel Haszard http://www.zyprexa-victims.com

Jan 12, 2010 7:02am EST  --  Report as abuse
terrylwalker wrote:
I’ve lost an Aunt to Zyprexa and a sister to Seroquel, Zyprexa was given to my aunt to get her to eat more she died of a stroke, my sister was told she had a psychiatric disorder. It is long overdue that they started figuring out whom this psychotropic drugs are toxic to.

Jan 12, 2010 8:32am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.